Liu Bin, Zhao Yangying, Guo Lianrong
Department of Gastroenterology.
The Health Check Center, The Second Hospital of Shandong University, Jinan, China.
Medicine (Baltimore). 2018 Oct;97(40):e11780. doi: 10.1097/MD.0000000000011780.
Pentraxin-3 (PTX3) is a glycoprotein involved in inflammation and immune regulation of cancer. The aim of this study was to evaluate the serum PTX3 level in patients with colorectal cancer (CRC) and analyze its prognostic significance.A total of 263 consecutive patients underwent radical resection for primary CRC and 126 healthy controls were enrolled in this study. Serum PTX3 level was measured within the day before surgery though enzyme-linked immunosorbent assays, comparing with the level of healthy control. Baseline demographic and clinical characteristics were recorded. The association between serum PTX3 level and survival outcome was analyzed by the Kaplan-Meier with Log-Rank test and Cox regression methods.Mean serum PTX3 level in CRC patients was higher than that of healthy control (13.8 ± 3.2ng/mL versus 3.3 ± 1.2ng/mL, P < .001). Finally, 55 (20.9%) patients out of all 263 patients studied had died during following-up period. All patients were divided into 2 groups using the optimal cutoff value (12.6 ng/mL) of PTX3 level using a sensitivity of 68.0% and a specificity of 71.7% as optimal conditions from receiver operating curve analysis. Patients with a PTX3≥12.6ng/mL had poorer 5 years overall survival rate (76.6% versus 67.8%, P = .025) patients with a PTX3 < 12.6ng/mL in univariate analysis and serum PTX3 level also been confirmed as an independent predictor for survival for CRC in multivariate analysis (Hazard ratio, 1.468; 95% [confidence interval] CI, 1.081-1.976; P < .001).Serum PTX3 level can serve as an independent prognostic biomarker for CRC patients after curative resection.
五聚体蛋白3（PTX3）是一种参与癌症炎症和免疫调节的糖蛋白。本研究旨在评估结直肠癌（CRC）患者的血清PTX3水平，并分析其预后意义。本研究共纳入263例接受原发性CRC根治性切除术的连续患者和126例健康对照。术前一天内通过酶联免疫吸附测定法测量血清PTX3水平，并与健康对照水平进行比较。记录基线人口统计学和临床特征。采用Kaplan-Meier对数秩检验和Cox回归方法分析血清PTX3水平与生存结果之间的关联。CRC患者的平均血清PTX3水平高于健康对照（13.8±3.2ng/mL对3.3±1.2ng/mL，P<0.001）。最终，在所有263例研究患者中，有55例（20.9%）在随访期间死亡。根据受试者工作曲线分析，以PTX3水平的最佳截断值（12.6ng/mL）、灵敏度68.0%和特异性71.7%为最佳条件，将所有患者分为两组。在单因素分析中，PTX3≥12.6ng/mL的患者5年总生存率较差（76.6%对67.8%，P=0.025），PTX3<12.6ng/mL的患者5年总生存率较好；在多因素分析中，血清PTX3水平也被确认为CRC生存的独立预测因子（风险比，1.468；95%[置信区间]CI，1.081-1.976；P<0.001）。血清PTX3水平可作为CRC患者根治性切除术后的独立预后生物标志物。
